LABT Lakewood-Amedex Biotherapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2079272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.7%
Debt / equity0.00x
Current ratio5.22x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| Cost of revenue | — | — | $507,292 | — | — | — |
| R&D expense | $733,096 | $503,020 | $182,147 | $752,931 | $146,901 | $169,703 |
| SG&A expense | $776,476 | $3.29M | $703,444 | $1.13M | $489,325 | $371,747 |
| Operating income | -$1.51M | -$3.79M | -$886,750 | -$1.88M | -$637,384 | -$542,609 |
| Interest expense | $0 | $10,633 | $38,219 | $37,808 | $23,949 | $1,315 |
| Net income | -$1.47M | -$3.77M | -$923,291 | -$1.91M | -$655,943 | -$539,617 |
| EBITDA | -$1.51M | -$3.79M | -$885,591 | -$1.88M | -$636,226 | -$541,450 |
| EPS (basic) | -0.62 | -2.75 | -0.20 | -3.46 | -1.66 | -0.15 |
| EPS (diluted) | -0.62 | -2.75 | -0.20 | -3.46 | -1.66 | -0.15 |
| Weighted avg. shares (diluted) | 2.39M | 1.42M | 7.00M | 696,880 | 694,450 | 6.94M |
| Balance sheet | ||||||
| Cash & equivalents | $2.82M | $2.58M | $11,709 | $658,410 | $1.27M | $477,009 |
| Short-term investments | $500,000 | $2.00M | — | — | — | — |
| Current assets | $3.51M | $4.85M | $50,626 | — | — | — |
| PP&E, net | $5,749 | $6,908 | $8,066 | — | — | — |
| Total assets | $3.60M | $4.96M | $196,343 | — | — | — |
| Current liabilities | $673,290 | $628,926 | $3.03M | — | — | — |
| Total liabilities | $673,290 | $628,926 | $3.04M | — | — | — |
| Shareholders' equity | $2.93M | $4.33M | -$2.84M | -$1.27M | -$683,251 | -$76,233 |
| Shares outstanding | 3.66M | 2.17M | 7.04M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$1.26M | -$2.10M | -$349,691 | -$610,045 | -$508,554 | -$404,089 |
| Investing cash flow | $1.50M | — | — | — | — | — |
| Financing cash flow | $0 | $6.68M | $125,000 | $0 | $1.30M | $200,000 |
| Depreciation & amortization | $1,159 | $1,159 | $1,159 | $1,159 | $1,158 | $1,159 |
| Stock-based compensation | $68,777 | $61,246 | $46,180 | $1.20M | $48,925 | $53,773 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.